Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ejaculatory disorders may affect screening for prostate cancer.

Jochen Walz1, Paul Perrotte, Andrea Gallina

  • 1Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada.

The Journal of Urology
|May 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

The Diagnostic Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Patients with Rising PSA After Radical Prostatectomy and Postoperative Radiotherapy: A Systematic Review and Meta-analysis.

European urology oncology·2026
Same author

When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era.

European urology oncology·2026
Same author

Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation.

Frontiers in oncology·2025
Same author

Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.

Clinical genitourinary cancer·2025
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Uro-Science.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
See all related articles

Half of men experience reduced ejaculatory volume and 1 in 10 experience ejaculatory pain before prostate cancer treatment. These sexual dysfunction issues significantly impact quality of life and should be assessed.

Area of Science:

  • Urology
  • Sexual Health
  • Oncology

Background:

  • Ejaculatory disorders are common after prostate cancer treatment.
  • Baseline prevalence of these disorders in men at risk for prostate cancer is unknown.

Purpose of the Study:

  • To determine the prevalence of ejaculatory disorders and associated bother in men without prostate cancer.
  • To identify factors associated with these disorders.

Main Methods:

  • 1,273 men without clinical evidence of prostate cancer completed the Danish Prostate Symptom Score.
  • The questionnaire assessed reduced ejaculatory volume, ejaculatory pain, and erectile dysfunction.

Main Results:

  • 46% reported reduced ejaculatory volume, with 66% bothered.

Related Experiment Videos

  • 11% reported ejaculatory pain, with 89% bothered.
  • 45% reported erectile dysfunction, with 73% bothered.

    • Conclusions:

    • Reduced ejaculatory volume is prevalent before treatment and associated with erectile dysfunction and age.
    • Ejaculatory pain affects 1 in 10 men and is a significant source of bother.
    • These findings highlight the importance of assessing baseline sexual function in men undergoing prostate cancer screening.